News

Monday July 27, 2020

27 July 2020 – Update on Phase 2b clinical study of XF-73

Destiny Pharma is pleased to announce a clinical protocol amendment has been agreed with FDA for its ongoing phase 2b study of lead asset XF-73.  Click here for press release. […]

Friday July 10, 2020

10 July 2020 – Pharma companies join forces to launch $1 billion fund to develop n...

Twenty-three leading biopharmaceutical companies have joined forces to invest $1 billion in a fund to develop new antibiotics, which are needed urgently to fight the worldwide rise in antimicrobial-resistant superbugs. […]